Adaptimmune Therapeutics (NASDAQ:ADAP) Sees Large Volume Increase

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) saw strong trading volume on Thursday . 24,669 shares traded hands during mid-day trading, a decline of 97% from the previous session’s volume of 732,775 shares.The stock last traded at $3.50 and had previously closed at $3.42.

Several research analysts have commented on the stock. Wells Fargo & Company upped their price objective on shares of Adaptimmune Therapeutics from $6.00 to $7.00 and gave the stock an “equal weight” rating in a report on Wednesday, September 22nd. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 10th. Finally, SVB Leerink restated a “hold” rating and issued a $7.00 price objective on shares of Adaptimmune Therapeutics in a report on Tuesday, November 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.75.

The company’s 50 day moving average is $3.98 and its 200-day moving average is $4.45.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Thursday, November 4th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.04). The business had revenue of $1.20 million during the quarter, compared to the consensus estimate of $1.20 million. Adaptimmune Therapeutics had a negative return on equity of 53.31% and a negative net margin of 2,499.92%. During the same quarter in the previous year, the business earned ($0.23) earnings per share. On average, equities analysts expect that Adaptimmune Therapeutics plc will post -0.69 EPS for the current year.

In other Adaptimmune Therapeutics news, CEO Adrian Rawcliffe sold 14,362 shares of the firm’s stock in a transaction dated Tuesday, January 11th. The shares were sold at an average price of $3.56, for a total transaction of $51,128.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders have sold 29,300 shares of company stock valued at $109,332. 18.89% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the business. US Bancorp DE increased its stake in Adaptimmune Therapeutics by 403.0% during the 3rd quarter. US Bancorp DE now owns 5,729 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 4,590 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Adaptimmune Therapeutics by 31.1% during the 3rd quarter. Lindbrook Capital LLC now owns 8,667 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 2,057 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Adaptimmune Therapeutics during the 2nd quarter valued at about $38,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Adaptimmune Therapeutics by 135.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,899 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 5,699 shares during the last quarter. Finally, Sigma Planning Corp purchased a new stake in shares of Adaptimmune Therapeutics during the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 71.38% of the company’s stock.

About Adaptimmune Therapeutics (NASDAQ:ADAP)

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Further Reading: Are sell-side analysts objective?

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.